Assembly Biosciences, Inc. (ASMB)
34.07
-0.73
(-2.10%)
USD |
NASDAQ |
Aug 28, 16:00
34.00
-0.07
(-0.21%)
After-Hours: 20:00
Assembly Biosciences Enterprise Value : 358.29M for Aug. 28, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 28, 2026 | 358.29M |
| August 27, 2026 | 372.78M |
| August 26, 2026 | 385.09M |
| August 25, 2026 | 383.30M |
| August 24, 2026 | 382.31M |
| August 21, 2026 | 364.44M |
| August 20, 2026 | 347.57M |
| August 19, 2026 | 353.72M |
| August 18, 2026 | 319.78M |
| August 17, 2026 | 277.70M |
| August 14, 2026 | 336.06M |
| August 13, 2026 | 276.51M |
| August 12, 2026 | 219.14M |
| August 11, 2026 | 223.31M |
| August 10, 2026 | 212.79M |
| August 07, 2026 | 211.60M |
| August 06, 2026 | 207.03M |
| August 05, 2026 | 208.72M |
| August 04, 2026 | 206.83M |
| August 03, 2026 | 185.39M |
| July 31, 2026 | 180.43M |
| July 30, 2026 | 199.29M |
| July 29, 2026 | 180.43M |
| July 28, 2026 | 189.56M |
| July 27, 2026 | 196.31M |
| Date | Value |
|---|---|
| July 24, 2026 | 189.16M |
| July 23, 2026 | 182.61M |
| July 22, 2026 | 198.89M |
| July 21, 2026 | 207.43M |
| July 20, 2026 | 179.44M |
| July 17, 2026 | 214.18M |
| July 16, 2026 | 194.92M |
| July 15, 2026 | 212.59M |
| July 14, 2026 | 213.18M |
| July 13, 2026 | 217.15M |
| July 10, 2026 | 225.89M |
| July 09, 2026 | 235.22M |
| July 08, 2026 | 252.29M |
| July 07, 2026 | 256.95M |
| July 06, 2026 | 255.56M |
| July 02, 2026 | 232.64M |
| July 01, 2026 | 211.79M |
| June 30, 2026 | 227.48M |
| June 29, 2026 | 204.35M |
| June 26, 2026 | 200.85M |
| June 25, 2026 | 161.44M |
| June 24, 2026 | 183.05M |
| June 23, 2026 | 201.81M |
| June 22, 2026 | 175.58M |
| June 18, 2026 | 164.30M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 202.07B |
| BridgeBio Pharma, Inc. | 17.65B |
| ACADIA Pharmaceuticals, Inc. | 4.128B |
| Alnylam Pharmaceuticals, Inc. | 31.39B |
| Anika Therapeutics, Inc. | 269.22M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.857M |
| Revenue (Quarterly) | 13.37M |
| Total Expenses (Quarterly) | 17.23M |
| EPS Diluted (Quarterly) | -0.2046 |
| Gross Profit Margin (Quarterly) | 99.85% |
| Profit Margin (Quarterly) | -28.84% |
| Earnings Yield | -0.22% |
| Normalized Earnings Yield | -0.2157 |